| Year |
Citation |
Score |
| 1998 |
Sutton KG, Siok C, Stea A, Zamponi GW, Heck SD, Volkmann RA, Ahlijanian MK, Snutch TP. Inhibition of neuronal calcium channels by a novel peptide spider toxin, DW13.3. Molecular Pharmacology. 54: 407-18. PMID 9687583 DOI: 10.1124/Mol.54.2.407 |
0.355 |
|
| 1997 |
Safayhi H, Haase H, Kramer U, Bihlmayer A, Roenfeldt M, Ammon HP, Froschmayr M, Cassidy TN, Morano I, Ahlijanian MK, Striessnig J. L-type calcium channels in insulin-secreting cells: biochemical characterization and phosphorylation in RINm5F cells. Molecular Endocrinology (Baltimore, Md.). 11: 619-29. PMID 9139805 DOI: 10.1210/Mend.11.5.9922 |
0.537 |
|
| 1994 |
Heck SD, Siok CJ, Krapcho KJ, Kelbaugh PR, Thadeio PF, Welch MJ, Williams RD, Ganong AH, Kelly ME, Lanzetti AJ, Gray WR, Phillips D, Parks TN, Jackson H, Ahlijanian MK, et al. Functional consequences of posttranslational isomerization of ser46 in a calcium channel toxin Science. 266: 1065-1068. PMID 7973665 DOI: 10.1126/Science.7973665 |
0.334 |
|
| 1994 |
Saccomano NA, Ahlijanian MK. Ca2+ channel toxins: Tools to study channel structure and function Drug Development Research. 33: 319-343. DOI: 10.1002/ddr.430330312 |
0.3 |
|
| 1993 |
Hell JW, Westenbroek RE, Warner C, Ahlijanian MK, Prystay W, Gilbert MM, Snutch TP, Catterall WA. Identification and differential subcellular localization of the neuronal class C and class D L-type calcium channel alpha 1 subunits. The Journal of Cell Biology. 123: 949-62. PMID 8227151 DOI: 10.1083/Jcb.123.4.949 |
0.619 |
|
| 1992 |
Dubel SJ, Starr TV, Hell J, Ahlijanian MK, Enyeart JJ, Catterall WA, Snutch TP. Molecular cloning of the alpha-1 subunit of an omega-conotoxin-sensitive calcium channel. Proceedings of the National Academy of Sciences of the United States of America. 89: 5058-62. PMID 1317580 DOI: 10.1073/Pnas.89.11.5058 |
0.622 |
|
| 1991 |
Ahlijanian MK, Striessnig J, Catterall WA. Phosphorylation of an alpha 1-like subunit of an omega-conotoxin-sensitive brain calcium channel by cAMP-dependent protein kinase and protein kinase. The Journal of Biological Chemistry. 266: 20192-7. PMID 1657916 |
0.61 |
|
| 1990 |
Westenbroek RE, Ahlijanian MK, Catterall WA. Clustering of L-type Ca2+ channels at the base of major dendrites in hippocampal pyramidal neurons. Nature. 347: 281-4. PMID 2169591 DOI: 10.1038/347281A0 |
0.535 |
|
| 1990 |
Ahlijanian MK, Westenbroek RE, Catterall WA. Subunit structure and localization of dihydropyridine-sensitive calcium channels in mammalian brain, spinal cord, and retina. Neuron. 4: 819-32. PMID 2163262 DOI: 10.1016/0896-6273(90)90135-3 |
0.568 |
|
| 1986 |
Ahlijanian MK, Takemori AE. Changes in adenosine receptor sensitivity in morphine-tolerant and -dependent mice. The Journal of Pharmacology and Experimental Therapeutics. 236: 615-20. PMID 3005548 |
0.5 |
|
| 1986 |
Ahlijanian MK, Takemori AE. The effect of chronic administration of caffeine on morphine-induced analgesia, tolerance and dependence in mice. European Journal of Pharmacology. 120: 25-32. PMID 3005000 DOI: 10.1016/0014-2999(86)90635-7 |
0.491 |
|
| 1986 |
Ahlijanian MK, Takemori AE. Cross-tolerance studies between caffeine and (-)-N6-(phenylisopropyl)-adenosine (PIA) in mice. Life Sciences. 38: 577-88. PMID 3003486 DOI: 10.1016/0024-3205(86)90051-2 |
0.464 |
|
| 1986 |
Ahlijanian MK, Takemori AE. Effects of caffeine and 8-phenyltheophylline on the actions of purines and opiates in the guinea-pig ileum. The Journal of Pharmacology and Experimental Therapeutics. 236: 171-6. PMID 3001283 |
0.473 |
|
| 1985 |
Ahlijanian MK, Takemori AE. Effects of (-)-N6-(R-phenylisopropyl)-adenosine (PIA) and caffeine on nociception and morphine-induced analgesia, tolerance and dependence in mice. European Journal of Pharmacology. 112: 171-9. PMID 2992993 DOI: 10.1016/0014-2999(85)90493-5 |
0.504 |
|
| 1984 |
Ahlijanian MK, Takemori AE. Effects of caffeine (C) and (-)-N6 (R-phenyl-isopropyl-adenosine) (PIA) on expression of morphine (M) dependence and cross tolerance to morphine Federation Proceedings. 43: No. 3807. |
0.483 |
|
| 1983 |
Ahlijanian MK, Takemori AE. Potentiation by 1-N6-phenylisopropyladenosine (1-PIA) of morphine (M)-induced analgesia, tolerance and dependence Federation Proceedings. 42: No. 324. |
0.476 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 1994 |
Heck SD, Siok CJ, Kelbaugh PR, Thadeio PF, Welch MJ, Williams RD, Ganong AH, Kelly ME, Lanzetti AJ, Phillips D, Ahlijanian MK, Saccomano NA. Correction: Functional consequences of post-translational isomerization of Ser46 in a calcium channel toxin (Science (1994) 11 Nov (1065)) Science. 266: 1464. |
0.294 |
|
| 1987 |
Ahlijanian MK, Halford MK, Cooper DM. Ca2+/calmodulin distinguishes between guanyl-5'-yl-imidodiphosphate- and opiate-mediated inhibition of rat striatal adenylate cyclase. Journal of Neurochemistry. 49: 1308-15. PMID 3625205 DOI: 10.1111/j.1471-4159.1987.tb10025.x |
0.252 |
|
| 1987 |
Ahlijanian MK, Cooper DM. Calmodulin may play a pivotal role in neurotransmitter-mediated inhibition and stimulation of rat cerebellar adenylate cyclase. Molecular Pharmacology. 32: 127-32. PMID 2885735 |
0.223 |
|
| 1988 |
Cooper DM, Ahlijanian MK, Perez-Reyes E. Calmodulin plays a dominant role in determining neurotransmitter regulation of neuronal adenylate cyclase. Journal of Cellular Biochemistry. 36: 417-27. PMID 2897969 DOI: 10.1002/jcb.240360410 |
0.22 |
|
| 1988 |
Ahlijanian MK, Cooper DM. Distinct interactions between Ca2+/calmodulin and neurotransmitter stimulation of adenylate cyclase in striatum and hippocampus. Cellular and Molecular Neurobiology. 8: 459-69. PMID 3224361 DOI: 10.1007/BF00711229 |
0.205 |
|
| 2014 |
Sivarao DV, Chen P, Yang Y, Li YW, Pieschl R, Ahlijanian MK. NR2B Antagonist CP-101,606 Abolishes Pitch-Mediated Deviance Detection in Awake Rats. Frontiers in Psychiatry. 5: 96. PMID 25140157 DOI: 10.3389/fpsyt.2014.00096 |
0.194 |
|
| 1987 |
Ahlijanian MK, Cooper DM. Antagonism of calmodulin-stimulated adenylate cyclase by trifluoperazine, calmidazolium and W-7 in rat cerebellar membranes. The Journal of Pharmacology and Experimental Therapeutics. 241: 407-14. PMID 3106618 |
0.189 |
|
| 2017 |
Rajamani R, Wu S, Rodrigo I, Gao M, Low S, Megson L, Wensel D, Pieschl R, Post-Munson D, Watson J, Langley DR, Ahlijanian M, Bristow L, Herrington J. A functional NaV1.7-NavAb chimera with a reconstituted high affinity ProTx-II binding site. Molecular Pharmacology. PMID 28645932 DOI: 10.1124/mol.117.108712 |
0.184 |
|
| 2011 |
Wu J, Shih HP, Vigont V, Hrdlicka L, Diggins L, Singh C, Mahoney M, Chesworth R, Shapiro G, Zimina O, Chen X, Wu Q, Glushankova L, Ahlijanian M, Koenig G, et al. Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment. Chemistry & Biology. 18: 777-93. PMID 21700213 DOI: 10.1016/J.Chembiol.2011.04.012 |
0.182 |
|
| 1986 |
Cooper DM, Bier-Laning CM, Halford MK, Ahlijanian MK, Zahniser NR. Dopamine, acting through D-2 receptors, inhibits rat striatal adenylate cyclase by a GTP-dependent process. Molecular Pharmacology. 29: 113-9. PMID 3005824 |
0.175 |
|
| 1988 |
Cooper DM, Caldwell KK, Perez-Reyes E, Ahlijanian MK, Schlegel W. Interactions between neurotransmitters that regulate cAMP and intracellular Ca2+ levels in the CNS. Advances in Experimental Medicine and Biology. 236: 217-27. PMID 2907238 DOI: 10.1007/978-1-4757-5971-6_17 |
0.163 |
|
| 2017 |
Post-Munson DJ, Pieschl RL, Molski TF, Graef JD, Hendricson AW, Knox RJ, McDonald IM, Olson RE, Macor JE, Weed MR, Bristow LJ, Kiss L, Ahlijanian MK, Herrington J. B-973, a novel piperazine positive allosteric modulator of the α7 nicotinic acetylcholine receptor. European Journal of Pharmacology. PMID 28132910 DOI: 10.1016/J.Ejphar.2017.01.037 |
0.161 |
|
| 2017 |
Robertson AS, Majchrzak MJ, Smith CM, Gagnon RC, Devidze N, Banks GB, Little SC, Nabbie F, Bounous DI, DiPiero J, Jacobsen LK, Bristow LJ, Ahlijanian MK, Stimpson SA. Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents. Neuromuscular Disorders : Nmd. PMID 28554556 DOI: 10.1016/J.Nmd.2017.05.009 |
0.154 |
|
| 2018 |
Qureshi IA, Tirucherai G, Ahlijanian MK, Kolaitis G, Bechtold C, Grundman M. A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimer's & Dementia (New York, N. Y.). 4: 746-755. PMID 30581980 DOI: 10.1016/j.trci.2018.10.007 |
0.143 |
|
| 2012 |
Rogers K, Felsenstein KM, Hrdlicka L, Tu Z, Albayya F, Lee W, Hopp S, Miller MJ, Spaulding D, Yang Z, Hodgdon H, Nolan S, Wen M, Costa D, Blain JF, ... ... Ahlijanian M, et al. Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Molecular Neurodegeneration. 7: 61. PMID 23249765 DOI: 10.1186/1750-1326-7-61 |
0.138 |
|
| 2000 |
Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP, McCarthy S, Coskran T, Carlo A, Seymour PA, Burkhardt JE, Nelson RB, McNeish JD. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proceedings of the National Academy of Sciences of the United States of America. 97: 2910-5. PMID 10706614 DOI: 10.1073/pnas.040577797 |
0.137 |
|
| 2003 |
Patzke H, Maddineni U, Ayala R, Morabito M, Volker J, Dikkes P, Ahlijanian MK, Tsai LH. Partial rescue of the p35-/- brain phenotype by low expression of a neuronal-specific enolase p25 transgene. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 2769-78. PMID 12684463 DOI: 10.1523/JNEUROSCI.23-07-02769.2003 |
0.126 |
|
| 2003 |
Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, Neve R, Ahlijanian MK, Tsai LH. APP processing is regulated by cytoplasmic phosphorylation. The Journal of Cell Biology. 163: 83-95. PMID 14557249 DOI: 10.1083/jcb.200301115 |
0.123 |
|
| 2019 |
Boxer AL, Qureshi I, Ahlijanian M, Grundman M, Golbe LI, Litvan I, Honig LS, Tuite P, McFarland NR, O'Suilleabhain P, Xie T, Tirucherai GS, Bechtold C, Bordelon Y, Geldmacher DS, et al. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. The Lancet. Neurology. 18: 549-558. PMID 31122495 DOI: 10.1016/S1474-4422(19)30139-5 |
0.119 |
|
| 2016 |
Sivarao DV, Chen P, Senapati A, Yang Y, Fernandes A, Benitex Y, Whiterock V, Li YW, Ahlijanian MK. 40 Hz Auditory Steady State Response is a Pharmacodynamic Biomarker for Cortical NMDA Receptors. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 26837462 DOI: 10.1038/Npp.2016.17 |
0.112 |
|
| 2004 |
Helal CJ, Sanner MA, Cooper CB, Gant T, Adam M, Lucas JC, Kang Z, Kupchinsky S, Ahlijanian MK, Tate B, Menniti FS, Kelly K, Peterson M. Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease. Bioorganic & Medicinal Chemistry Letters. 14: 5521-5. PMID 15482916 DOI: 10.1016/j.bmcl.2004.09.006 |
0.109 |
|
| 2015 |
Sankaranarayanan S, Barten DM, Vana L, Devidze N, Yang L, Cadelina G, Hoque N, DeCarr L, Keenan S, Lin A, Cao Y, Snyder B, Zhang B, Nitla M, Hirschfeld G, ... ... Ahlijanian M, et al. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. Plos One. 10: e0125614. PMID 25933020 DOI: 10.1371/Journal.Pone.0125614 |
0.108 |
|
| 2014 |
Toyn JH, Thompson LA, Lentz KA, Meredith JE, Burton CR, Sankaranararyanan S, Guss V, Hall T, Iben LG, Krause CM, Krause R, Lin XA, Pierdomenico M, Polson C, Robertson AS, ... ... Ahlijanian MK, et al. Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780. International Journal of Alzheimer's Disease. 2014: 431858. PMID 25097793 DOI: 10.1155/2014/431858 |
0.104 |
|
| 2011 |
Barten DM, Cadelina GW, Hoque N, DeCarr LB, Guss VL, Yang L, Sankaranarayanan S, Wes PD, Flynn ME, Meredith JE, Ahlijanian MK, Albright CF. Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. Journal of Alzheimer's Disease : Jad. 24: 127-41. PMID 21422517 DOI: 10.3233/Jad-2011-110161 |
0.104 |
|
| 2016 |
Soares HD, Gasior M, Toyn JH, Wang JS, Hong Q, Berisha F, Furlong MT, Raybon J, Lentz KA, Sweeney F, Zheng N, Akinsanya B, Berman RM, Thompson LA, Olson RE, ... ... Ahlijanian MK, et al. The Gamma Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and CSF of Healthy Volunteers. The Journal of Pharmacology and Experimental Therapeutics. PMID 27189973 DOI: 10.1124/Jpet.116.232256 |
0.099 |
|
| 2017 |
Huang RY, Iacob RE, Sankaranarayanan S, Yang L, Ahlijanian M, Tao L, Tymiak AA, Chen G. Probing Conformational Dynamics of Tau Protein by Hydrogen/Deuterium Exchange Mass Spectrometry. Journal of the American Society For Mass Spectrometry. PMID 28971440 DOI: 10.1007/s13361-017-1815-8 |
0.096 |
|
| 2013 |
Meredith JE, Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ, Slemmon JR, Portelius E, Zetterberg H, Blennow K, Soares H, Ahlijanian M, Albright CF. Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease. Plos One. 8: e76523. PMID 24116116 DOI: 10.1371/Journal.Pone.0076523 |
0.091 |
|
| 2003 |
Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, Gaynor K, LaFrancois J, Wang L, Kondo T, Davies P, Burns M, Veeranna, Nixon R, Dickson D, ... ... Ahlijanian M, et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron. 38: 555-65. PMID 12765608 DOI: 10.1016/S0896-6273(03)00259-9 |
0.085 |
|
| 2006 |
Ahlijanian MK. Evidence for Neuropathology in Transgenic Mice Overexpressing p25, an Activator of cdk5 Cns Drug Reviews. 6: 34-34. DOI: 10.1111/j.1527-3458.2000.tb00178.x |
0.084 |
|
| 2017 |
Robertson AS, Iben LG, Wei C, Meredith JE, Drexler DM, Banks M, Vite GD, Olson RE, Thompson LA, Albright CF, Ahlijanian MK, Toyn JH. Synergistic inhibition of Aβ production by combinations of γ-secretase modulators. European Journal of Pharmacology. PMID 28690193 DOI: 10.1016/J.Ejphar.2017.07.019 |
0.083 |
|
| 2023 |
Foster K, Manca M, McClure K, Koivula P, Trojanowski JQ, Havas D, Chancellor S, Goldstein L, Brunden KR, Kraus A, Ahlijanian MK. Preclinical characterization and IND-enabling safety studies for PNT001, an antibody that recognizes cis-pT231 tau. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37002928 DOI: 10.1002/alz.13028 |
0.082 |
|
| 2019 |
Boy KM, Guernon JM, Zuev DS, Xu L, Zhang Y, Shi J, Marcin LR, Higgins MA, Wu YJ, Krishnananthan S, Li J, Trehan A, Smith D, Toyn JH, Meredith JE, ... ... Ahlijanian MK, et al. Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481. Acs Medicinal Chemistry Letters. 10: 312-317. PMID 30891132 DOI: 10.1021/Acsmedchemlett.8B00541 |
0.081 |
|
| 2009 |
Helal CJ, Kang Z, Lucas JC, Gant T, Ahlijanian MK, Schachter JB, Richter KE, Cook JM, Menniti FS, Kelly K, Mente S, Pandit J, Hosea N. Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's disease. Bioorganic & Medicinal Chemistry Letters. 19: 5703-7. PMID 19700321 DOI: 10.1016/j.bmcl.2009.08.019 |
0.078 |
|
| 2013 |
Easton A, Sankaranarayanan S, Tanghe A, Terwel D, Lin AX, Hoque N, Bourin C, Gu H, Ahlijanian M, Bristow L. Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer's disease. Psychopharmacology. 230: 279-89. PMID 23783773 DOI: 10.1007/s00213-013-3152-3 |
0.076 |
|
| 2003 |
Lau LF, Ahlijanian MK. Role of cdk5 in the pathogenesis of Alzheimer's disease. Neuro-Signals. 12: 209-14. PMID 14673207 DOI: 10.1159/000074622 |
0.075 |
|
| 2016 |
Toyn JH, Boy KM, Raybon J, Meredith JE, Roberston AS, Guss V, Hoque N, Sweeney F, Zhuo X, Clarke W, Snow K, Denton RR, Zuev D, Thompson LA, Morrison J, ... ... Ahlijanian MK, et al. Robust translation of GSM pharmacology across preclinical species and human subjects. The Journal of Pharmacology and Experimental Therapeutics. PMID 27189974 DOI: 10.1124/Jpet.116.232249 |
0.074 |
|
| 2017 |
Cantone JL, Polson C, Wei C, Guss V, Ahlijanian MK, Meredith JE, Drexler DM. Utility of high resolution accurate mass spectrometry (HRMS) in the mass isotopomer distribution analysis (MIDA) of CSF proteins modified by stable isotope labeling in mammals (SILAM) methodology applied to neurodegenerative diseases Analytical Methods. 9: 3477-3484. DOI: 10.1039/C7Ay00869D |
0.071 |
|
| 2016 |
Wu YJ, Guernon J, Rajamani R, Toyn JH, Ahlijanian MK, Albright CF, Muckelbauer J, Chang C, Camac D, Macor JE, Thompson LA. Discovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 27816517 DOI: 10.1016/J.Bmcl.2016.10.055 |
0.07 |
|
| 2016 |
Wu YJ, Guernon J, Shi J, Marcin L, Higgins M, Rajamani R, Muckelbauer JK, Lewis HA, Chang C, Camac D, Toyn JH, Ahlijanian MK, Albright CF, Macor JE, Thompson LA. Discovery of S3-truncated, C-6 heteroaryl substituted aminothiazine β-site APP cleaving enzyme-1 (BACE1) inhibitors. Journal of Medicinal Chemistry. PMID 27559936 DOI: 10.1021/Acs.Jmedchem.6B01012 |
0.07 |
|
| 2016 |
Wu YJ, Guernon J, Yang F, Snyder L, Shi J, Mcclure A, Rajamani R, Park H, Ng A, Lewis H, Chang C, Camac D, Toyn JH, Ahlijanian MK, Albright CF, et al. Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain Aβ Reduction in Rodents. Acs Medicinal Chemistry Letters. 7: 271-6. PMID 26985314 DOI: 10.1021/Acsmedchemlett.5B00432 |
0.067 |
|
| 2020 |
Rusilowicz-Jones EV, Jardine J, Kallinos A, Pinto-Fernandez A, Guenther F, Giurrandino M, Barone FG, McCarron K, Burke CJ, Murad A, Martinez A, Marcassa E, Gersch M, Buckmelter AJ, Kayser-Bricker KJ, ... ... Ahlijanian MK, et al. USP30 sets a trigger threshold for PINK1-PARKIN amplification of mitochondrial ubiquitylation. Life Science Alliance. 3. PMID 32636217 DOI: 10.26508/lsa.202000768 |
0.063 |
|
| 2020 |
Zhang Y, Boy KM, Wu YJ, Ramirez A, Toyn JH, Ahlijanian MK, Albright CF, Zhuo X, Johnson BM, Denton RR, Olson RE, Thompson LA, Macor JE. Synthesis of Functionalized Derivatives of the Gamma-Secretase Modulator BMS-932481 and Identification of its Major Metabolite. Bioorganic & Medicinal Chemistry Letters. 127530. PMID 32890687 DOI: 10.1016/J.Bmcl.2020.127530 |
0.061 |
|
| 2015 |
Wagshal D, Sankaranarayanan S, Guss V, Hall T, Berisha F, Lobach I, Karydas A, Voltarelli L, Scherling C, Heuer H, Tartaglia MC, Miller Z, Coppola G, Ahlijanian M, Soares H, et al. Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy. Journal of Neurology, Neurosurgery, and Psychiatry. 86: 244-50. PMID 24899730 DOI: 10.1136/Jnnp-2014-308004 |
0.059 |
|
| 2023 |
Shin SS, Mazandi VM, Schneider ALC, Morton S, Starr JP, Weeks MK, Widmann NJ, Jang DH, Kao SH, Ahlijanian MK, Kilbaugh TJ. Exploring the Therapeutic Potential of Phosphorylated -Tau Antibody in a Pig Model of Traumatic Brain Injury. Biomedicines. 11. PMID 37509447 DOI: 10.3390/biomedicines11071807 |
0.054 |
|
| 2014 |
Scherling CS, Hall T, Berisha F, Klepac K, Karydas A, Coppola G, Kramer JH, Rabinovici G, Ahlijanian M, Miller BL, Seeley W, Grinberg LT, Rosen H, Meredith J, Boxer AL. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Annals of Neurology. 75: 116-26. PMID 24242746 DOI: 10.1002/Ana.24052 |
0.042 |
|
| 2016 |
Newberry K, Wang S, Hoque N, Ahlijanian MK, Kiss L, Herrington J, Graef JD. Development of a Spontaneously Active Dorsal Root Ganglia Assay using Multi-well Multielectrode Arrays. Journal of Neurophysiology. jn.01122.2015. PMID 27052585 DOI: 10.1152/jn.01122.2015 |
0.038 |
|
| 2012 |
Meredith J, Slemmon R, Guss V, Lanzetti A, Sankaranarayanan S, Soares H, Blennow K, Albright C, Ahlijanian M. P2-039: Novel tau fragments are present in human CSF Alzheimer's & Dementia. 8: P276-P277. DOI: 10.1016/j.jalz.2012.05.742 |
0.038 |
|
| 2014 |
Toyn JH, Ahlijanian MK. Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β. Alzheimer's Research & Therapy. 6: 14. PMID 25031632 DOI: 10.1186/alzrt244 |
0.023 |
|
| Hide low-probability matches. |